US 12,460,207 B2
Inhibiting APE2 expression in a subject treated with a drug agent that causes increased APE2 expression
Jianjun Zhao, Cleveland, OH (US); and Jianhong Lin, Cleveland, OH (US)
Assigned to The Cleveland Clinic Foundation, Cleveland, OH (US)
Filed by The Cleveland Clinic Foundation, Cleveland, OH (US)
Filed on Mar. 16, 2022, as Appl. No. 17/696,510.
Claims priority of provisional application 63/161,779, filed on Mar. 16, 2021.
Prior Publication US 2022/0307034 A1, Sep. 29, 2022
Int. Cl. C12N 15/113 (2010.01); A61K 31/085 (2006.01); A61K 31/14 (2006.01); A61K 31/282 (2006.01); A61K 31/381 (2006.01); A61K 31/427 (2006.01); A61K 31/454 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/549 (2006.01); A61K 31/7056 (2006.01); A61K 33/243 (2019.01); A61K 39/395 (2006.01); A61P 13/12 (2006.01)
CPC C12N 15/1137 (2013.01) [A61K 31/085 (2013.01); A61K 31/14 (2013.01); A61K 31/282 (2013.01); A61K 31/381 (2013.01); A61K 31/427 (2013.01); A61K 31/454 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/549 (2013.01); A61K 31/7056 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61P 13/12 (2018.01); C12N 2310/11 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A method of protecting kidney function in a subject comprising: treating a subject having cisplatin-treated cancer with:
i) an apurinic/apyrimidinic endonuclease 2 (APE2) inhibitor, wherein said APE2 inhibitor comprises: i) an antisense oligonucleotide directed toward APE2 mRNA or DNA, or ii) an siRNA sequence directed toward APE2 mRNA, and
ii) a drug agent that causes increased expression of APE2 in said subject, wherein said drug agent comprises cisplatin,
and wherein said subject is administered an amount of said drug agent that is at least 15 mg/kg, and causes acute kidney injury in said subject in the absence of said APE2 inhibitor, and
wherein said APE2 inhibitor is administered before said drug agent.